文献速递血栓与止血

血栓性血小板减少性紫癜:1995年至2015年的诊断标准、临床特征与长期结局

Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015.
PubMed 文献 · Blood Adv · 2017-04-06

基于俄克拉何马血栓性血小板减少性紫癜(TTP)登记库1995年11月至2015年12月的资料,363例临床疑似TTP患者中78例(21%)经ADAMTS13活性<10%和临床特征支持诊断;47%无或仅有轻微神经系统异常,95%无或仅有轻微血清肌酐异常;10例(13%)死亡,其中3例死于血浆置换并发症;2003年12月后部分患者使用利妥昔单抗,所需血浆置换次数更少且复发更少。

要点

  • 363例疑似TTP患者中78例(21%)由ADAMTS13活性<10%和临床特征支持诊断。
  • 47%无或仅有轻微神经系统异常,95%无或仅有轻微血清肌酐异常。
  • 10例(13%)死亡,其中3例死于血浆置换并发症。

核心结论

  • 在363例初始临床疑似TTP的患者中,78例(21%)的诊断由ADAMTS13活性<10%和临床特征共同支持。
  • 微血管病性溶血性贫血和血小板减少并非在所有患者中都很严重。
  • 在2003年12月开始部分患者使用利妥昔单抗之后就诊的患者,所需血浆置换治疗次数更少且复发更少。

研究设计与样本

  • 研究为俄克拉何马血栓性血小板减少性紫癜(TTP)登记库的经验描述,时间范围为1995年11月至2015年12月。
  • 纳入363例初始临床疑似TTP的患者,全部通过荧光共振能量转移(FRET)和免疫印迹(IB)两种方法检测ADAMTS13活性。

主要发现

  • 363例疑似TTP患者中,78例(21%)由ADAMTS13活性<10%和临床特征支持诊断。
  • 60例经两种方法检测ADAMTS13活性均<10%,15例仅经FRET检测<10%,3例仅经IB检测<10%。
  • 5例经一种方法检测ADAMTS13活性<10%的患者有替代临床诊断而非TTP。
  • 2例具有TTP特征性临床特征(微血管病性溶血性贫血和血小板减少,无替代诊断)且多次复发的患者,最初两种方法检测ADAMTS13活性均>10%。
  • ADAMTS13抑制物滴度与就诊特征或结局无关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our objective was to describe new observations from the Oklahoma Thrombotic Thrombocytopenic Purpura (TTP) Registry experience (November 1995 through December 2015) on the diagnosis of TTP along with patients' clinical features and their outcomes. Among 363 patients with an initial episode of clinically suspected TTP, the diagnosis of TTP was supported by both ADAMTS13 activity <10% and clinical features in 78 patients (21%). ADAMTS13 activity was measured in all 363 patients by 2 methods: fluorescence resonance energy transfer (FRET) and immunoblotting (IB). Sixty patients had ADAMTS13 activity <10% by both methods, 15 had ADAMTS13 <10% only by FRET, and 3 had ADAMTS13 <10% only by IB. Five patients with ADAMTS13 activity <10% by 1 method had an alternative clinical diagnosis, not TTP. Two patients with characteristic clinical features of TTP (microangiopathic hemolytic anemia and thrombocytopenia, no alternative diagnosis) and multiple relapses initially had ADAMTS13 activity >10% by both measurements. ADAMTS13 inhibitor titers were not associated with presenting features or outcomes. Microangiopathic hemolytic anemia and thrombocytopenia were not severe in all patients. Forty-seven percent of patients had no or minor neurologic abnormalities; 95% had no or minor serum creatinine abnormalities. Ten patients (13%) died, 2 before completing 1 plasma exchange (PEX); 3 deaths were attributed to PEX complications. For patients presenting after we began using rituximab in some patients (December 2003), fewer PEX treatments were required and fewer relapses occurred. Patients with their first relapse presented with higher platelet counts and hematocrits and lower lactate dehydrogenase levels and required fewer PEX treatments compared with their initial episodes.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Page EE, Kremer Hovinga JA, Terrell DR, et al. Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Adv. 2017. PMID: 29296701. doi:10.1182/bloodadvances.2017005124

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。